

MS PETITION
Docket No.: 1422-0714PUS1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Masazumi YASUMOTO et al.

Application No.: 10/574,904

Confirmation No.: 7136

Filed: April 6, 2006

Art Unit: N/A

For: COMPOSITION FOR INHIBITING
FUNCTION OF HUMAN FLT3

Examiner: Not Yet Assigned

PETITION TO WITHDRAW ABANDONMENT
SINCE REPLY WAS TIMELY FILED

MS Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Madam:

In response to the Notice of Abandonment mailed May 15, 2009, which issued in connection with the above-identified application, this is a Petition to withdraw the "abandonment status" of the present application, since a Reply was timely filed on November 17, 2008.

1. EVIDENCE

As evidence of the fact that a Reply was timely filed, enclosed herewith are the following:

- a copy of the Reply filed November 17, 2008;
- a text copy of the sequence listing; and

- a copy of the e-filing confirmation copy.

2. TERMINAL DISCLAIMER

☒ The present application was filed on or after May 29, 2000. Accordingly, no Terminal Disclaimer is necessary. It is noted that the present Petition is being timely filed within two (2) months of the mailing date of the Notice of Abandonment. Accordingly, no reduction in patent term adjustment should be made, in accordance with the provisions of 37 C.F.R. § 1.704(c)(4).

☐ The present application was filed on or after June 8, 1995 but before May 29, 2000. The present Petition is being timely filed within two (2) months of the mailing date of the Notice of Abandonment. Accordingly, no Terminal Disclaimer under 37 C.F.R. § 1.321(a) is necessary. See MPEP § 711.03(c).

☐ The present application was filed on or after June 8, 1995 but before May 29, 2000. The present Petition is being filed more than two (2) months from the mailing date of the Notice of Abandonment. Accordingly, a Terminal Disclaimer under 37 C.F.R. § 1.321(a) and the required fee set forth in 37 CFR 1.20(d) are being submitted concurrently herewith. The period being disclaimed is equivalent to the period between (1) the date that is two months after the mail date of the notice of abandonment and (2) the filing date of the present petition to withdraw the holding of abandonment. See MPEP § 711.03(c).

Applicants were not accorded a notice from the USPTO advising of the exclusion of the text copy of the sequence listing when submitting the response on November 17, 2008. Therefore, a notice of abandonment was incorrectly mailed. It is requested that the abandonment status of the present application be immediately removed so that prosecution may resume with full consideration and entry into the record of the timely filed Reply.

If the U.S. Patent Examiner has any questions regarding the above matters, please contact Applicants' representative, Marc S. Weiner, at the phone number listed below.

It is submitted that no fees are required for filing this Petition, since the error occurred as an oversight on the part of the U.S. Patent and Trademark Office since the Response was timely filed on November 17, 2008.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Dated: JUN 9 2009

Respectfully submitted,



By _____
Marc S. Weiner
Registration No.: 32,181
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant

Attachments: Copy of Reply filed November 17, 2008
Text copy of sequence listing
Copy of e-mail confirmation of November 17, 2008 filing

Electronic Acknowledgement Receipt

COPY

EFS ID:	4301948
Application Number:	10574904
International Application Number:	
Confirmation Number:	7136
Title of Invention:	Composition for inhibiting function of human flt3
First Named Inventor/Applicant Name:	Masazumi Yasumoto
Customer Number:	02292
Filer:	Marc S. Weiner/Bonnie Hughes
Filer Authorized By:	Marc S. Weiner
Attorney Docket Number:	14220714PUS1
Receipt Date:	17-NOV-2008
Filing Date:	
Time Stamp:	16:34:41
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no				
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		20081117Amendment.pdf	315567 01c4b14d91e9af8d4b9ba8eeabe04725eb64e027	yes	19

Multipart Description/PDF files in .zip description			
Document Description	Start	End	
Miscellaneous Incoming Letter	1	1	
Amendment/Req. Reconsideration-After Non-Final Reject	2	2	
Sequence Listing	3	3	
Applicant Arguments/Remarks Made in an Amendment	4	4	
Sequence Listing	5	17	
Miscellaneous Incoming Letter	18	19	

Warnings:

Information:

2	Sequence Listing	SequenceListing.pdf	3164057	no	10
			5cf1e540818df9f681e68cb4612e6d0a94cf47d4		

Warnings:

Information:

Total Files Size (in bytes):	3479624
------------------------------	---------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.


National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

COPY

AMENDMENT TRANSMITTAL LETTER			Docket No. 1422-0714PUS1		
Application No. 10/574,904-Conf. #7136	Filing Date April 6, 2006	Examiner Not Yet Assigned	Art Unit N/A		
Applicant(s): Masazumi YASUMOTO et al.					
Invention: COMPOSITION FOR INHIBITING FUNCTION OF HUMAN FLT3					
MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	21	- 21 =	0	x 52.00	0.00
Independent Claims	4	- 4 =	0	x 220.00	0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00
<input checked="" type="checkbox"/> Large Entity <input type="checkbox"/> Small Entity					
<input checked="" type="checkbox"/> No additional fee is required for this amendment.					
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of \$ _____. A duplicate copy of this sheet is enclosed.					
<input type="checkbox"/> A check in the amount of \$ _____ is enclosed.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>02-2448</u> as described below. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> Credit any overpayment.					
<input checked="" type="checkbox"/> Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.					
 #43575				Dated: <u>NOV 17 2008</u>	
Marc S. Weiner Attorney Reg. No.: 32,181 <i>for</i>					
BIRCH, STEWART, KOLASCH & BIRCH, LLP 8110 Gatehouse Road Suite 100 East P.O. Box 747 Falls Church, Virginia 22040-0747 (703) 205-8000					

EAC

BOX SEQUENCE
PATENT
1422-0714PUS1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Masazumi YASUMOTO et al.

Application No.: 10/574,904

Confirmation No.: 7136

Filed: April 6, 2006

Art Unit: N/A

For: COMPOSITION FOR INHIBITING
FUNCTION OF HUMAN FLT3

Examiner: Not Yet Assigned

AMENDMENT

Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply mailed October 20, 2008 (a copy of which is attached hereto), the following amendments and remarks are respectfully submitted in connection with the above-identified application.

This Reply includes:

- Amendments** to the Sequence Listing begin on page 2 of this paper.
- Remarks/Arguments** begin on page 3 of this paper.
- An **Appendix** including the paper and electronic CRF copy of the Sequence Listing is attached following page 3 of this paper.

AMENDMENTS TO THE SEQUENCE LISTING

IN THE SEQUENCE LISTING

Please replace the Sequence Listing of record with the Substitute Sequence Listing enclosed herewith.

REMARKS

Enclosed herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification. Also submitted herewith in full compliance with 37 C.F.R. §§1.821-1.825 is an electronic CRF copy of the Substitute Sequence Listing. The electronic CRF copy of the Substitute Sequence Listing, file "2008-11-12 1422-0714PUS1.txt", is identical to the paper copy, except that it lacks formatting. In no way do the paper copy nor the electronic CRF copy of the Substitute Sequence Listing introduce new matter into the application.


The Sequence Listing is updated to identify the present application by filing date and serial number and to correct matters of form. No new matter is introduced by these amendments.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,


NOV 17 2008

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Marc S. Weiner, #32,181 *for*

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

MSW/psq
1422-0714PUS1

 Attachments:

Electronic CRF Copy of Substitute Sequence Listing
Paper Copy of Substitute Sequence Listing
Copy of Notice to Comply

COPY

<110> YASUMOTO, Masazumi
SHIMADA, Masamitsu
HINO, Fumitsugu
KATO, Ikunoshin

<120> COMPOSITION FOR INHIBITING FUNCTION OF HUMAN FLT3

<130> 1422-0714PUS1

<140> US 10/574,904
<141> 2006-04-06

<150> PCT/JP2004/014851
<151> 2004-10-07

<150> JP2003-350253
<151> 2003-10-09

<160> 40

<170> PatentIn version 3.5

<210> 1
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide: A partial cDNA sequence of ATP-binding site

<400> 1
aaggtactag gatcaggtgc t 21

<210> 2
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide: Designated as SEQ1-S

<220>
<221> misc_feature
<222> (1)..(19)
<223> ribonucleotides

<220>
<221> misc_feature
<222> (20)..(21)
<223> deoxyribonucleotides

<400> 2
gguacuagga ucaggugcut t 21

<210> 3
<211> 21

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: Designated as SEQ1-AS

 <220>
 <221> misc_feature
 <222> (1)..(19)
 <223> ribonucleotides

 <220>
 <221> misc_feature
 <222> (20)..(21)
 <223> deoxyribonucleotides

 <400> 3
 agcaccugau ccuaguacct t 21

 <210> 4
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: A partial cDNA sequence of TK domain

 <400> 4
 aacaggagtc tcaatccagg t 21

 <210> 5
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: Designated as SEQ2-S

 <220>
 <221> misc_feature
 <222> (1)..(19)
 <223> ribonucleotides

 <220>
 <221> misc_feature
 <222> (20)..(21)
 <223> deoxyribonucleotides

 <400> 5
 caggagucuc aauccaggut t 21

 <210> 6
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide: Designated as SEQ2-AS

<220>
<221> misc_feature
<222> (1)..(19)
<223> ribonucleotides

<220>
<221> misc_feature
<222> (20)..(21)
<223> deoxyribonucleotides

<400> 6
accuggauug agacuccugt t 21

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide: A partial cDNA sequence of FLT3/ITD domain

<400> 7
aatatgaata tgatctcaaa t 21

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide: Designated as SEQ3-S

<220>
<221> misc_feature
<222> (1)..(19)
<223> ribonucleotides

<220>
<221> misc_feature
<222> (20)..(21)
<223> deoxyribonucleotides

<400> 8
uauaauaug aucucaaaut t 21

<210> 9
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide: Designated as SEQ3-AS

<220>
 <221> misc_feature
 <222> (1)..(19)
 <223> ribonucleotides

<220>
 <221> misc_feature
 <222> (20)..(21)
 <223> deoxyribonucleotides

<400> 9
 auuugagauc auaucauat t 21

<210> 10
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide: A partial cDNA sequence of bcr/abl chimera domain

<400> 10
 aagcagagtt caaaagcccu u 21

<210> 11
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide

<220>
 <220>
 <221> misc_feature
 <222> (1)..(19)
 <223> ribonucleotides

<220>
 <221> misc_feature
 <222> (20)..(21)
 <223> deoxyribonucleotides

<400> 11
 gcagaguuca aaagcccuut t 21

<210> 12
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(19)
 <223> ribonucleotides

<220>
 <221> misc_feature
 <222> (20)..(21)
 <223> deoxyribonucleotides

<400> 12
 aagggcuuuu gaacucugct t 21

<210> 13
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide: PCR primer FLT11F for amplifying a gene encoding FLT3

<400> 13
 gcaatttagg tatgaaagcc agc 23

<210> 14
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide: PCR primer FLT12R for amplifying a gene encoding FLT3

<400> 14
 ctttcagcat ttgacggca acc 23

<210> 15
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide: PCR primer G1 for amplifying a gene encoding GAPDH

<400> 15
 caacagcctc aagatcatca gc 22

<210> 16
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide: PCR primer G2 for amplifying a gene encoding GAPDH

<400> 16
ttctagacgg caggtcaggt c

21

<210> 17
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide: Expression cassette FLT3SI1F for
expressing siRNA for ATP-binding domain

<220>
<221> misc_feature
<222> (1)..(5)
<223> BamHI restriction site

<220>
<221> misc_feature
<222> (26)..(34)
<223> loop site

<220>
<221> misc_feature
<222> (54)..(59)
<223> RNA polymerase III terminator

<400> 17
gatcccggtg ctaggatcag gtgctttcaa gagaagcacc tgatcctagt accttttttg
gaaa

60

64

<210> 18
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic oligonucleotide: Expression cassette FLT3SI1R for
expressing siRNA for ATP-binding domain

<220>
<221> misc_feature
<222> (1)..(5)
<223> HindIII restriction site

<220>
<221> misc_feature
<222> (10)..(15)
<223> RNA polymerase III terminator site

<220>
<221> misc_feature
<222> (35)..(43)
<223> loop

<400> 18
agctttttcca aaaaagggtac taggatcagg tgctttcttt gaaagcacct gatcctagta

60

ccgg

64

<210> 19
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> synthetic oligonucleotide: Expression cassette FLT3CON1F for
 expressing control sequence

<220>
 <221> misc_feature
 <222> (1)..(5)
 <223> BamHI restriction site

<220>
 <221> misc_feature
 <222> (26)..(34)
 <223> loop site

<220>
 <221> misc_feature
 <222> (54)..(59)
 <223> RNA polymerase III terminator site

<400> 19
 gatcccgag tcgtagctgc agtatttcaa gagaatactg cagctacgac tccttttttg

60

gaaa

64

<210> 20
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> synthetic oligonucleotide: Expression cassette FLT3CON1R for
 expressing control sequence

<220>
 <221> misc_feature
 <222> (1)..(5)
 <223> HindIII restriction site

<220>
 <221> misc_feature
 <222> (10)..(15)
 <223> RNA polymerase III terminator site

<220>
 <221> misc_feature
 <222> (35)..(43)
 <223> loop

<400> 20
 agcttttcca aaaaaggagt cgtagctgca gtatttcttt gaaatactgc agctacgact

60

ccgg

64

<210> 21
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide: Expression cassette FLT3SI3F for
 expressing siRNA for FLT3/ITD domain

<220>
 <221> misc_feature
 <222> (1)..(5)
 <223> BamHI restriction site

<220>
 <221> misc_feature
 <222> (26)..(34)
 <223> loop site

<220>
 <221> misc_feature
 <222> (54)..(59)
 <223> RNA polymerase III terminator

<400> 21
 gatccctatg aatatgatct caaatttcaa gagaatttga gatcatattc atatTTTTTg 60
 gaaa 64

<210> 22
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide: Expression cassette FLT3SI3R for
 expressing siRNA for FLT3/ITD domain

<220>
 <221> misc_feature
 <222> (1)..(5)
 <223> HindIII restriction site

<220>
 <221> misc_feature
 <222> (10)..(15)
 <223> RNA polymerase III terminator site

<220>
 <221> misc_feature
 <222> (35)..(43)
 <223> loop

<400> 22
 agcttttcca aaaaatatga atatgatctc aaatttcttt gaaatttgag atcatattca 60
 tagg 64

<210> 23
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide: Expression cassette FLT3CON3F for
 expressing control sequence

<220>
 <221> misc_feature
 <222> (1)..(5)
 <223> BamHI restriction site

<220>
 <221> misc_feature
 <222> (26)..(34)
 <223> loop site

<220>
 <221> misc_feature
 <222> (54)..(59)
 <223> RNA polymerase III terminator site

<400> 23
 gatccaata atttgcttca aagatttcaa gagaatcttt gaagcaaatt attttttttg 60
 gaaa 64

<210> 24
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide: Expression cassette FLT3CON3R for
 expressing control sequence

<220>
 <221> misc_feature
 <222> (1)..(5)
 <223> HindIII restriction site

<220>
 <221> misc_feature
 <222> (10)..(15)
 <223> RNA polymerase III terminator site

<220>
 <221> misc_feature
 <222> (35)..(43)
 <223> loop

<400> 24
 agctttttcca aaaaaaataa ttgcttcaa agattctctt gaaatctttg aagcaaatta 60
 ttgg 64

<210> 25
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: 5' sequencing primer

 <400> 25
 taatacgact cactataggg 20

 <210> 26
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: 3' sequencing primer

 <400> 26
 aggcgattaa gttgggta 18

 <210> 27
 <211> 144
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: Juxtamembrane domain

 <400> 27
 tgtcacaagt acaaaaagca atttaggtat gaaagccagc tacagatggg acaggtgacc 60
 ggctcctcag ataatgagta cttctacgtt gatttcagag aatatgaata tgatctcaaa 120
 tgggagtttc caagagaaaa ttta 144

 <210> 28
 <211> 471
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: Tyrosine kinase domain

 <400> 28
 acgcaacagc ttatggaatt agcaaaacag gagtctcaat ccagggtgcc gtcaaaatgc 60
 tgaaagaaaa agcagacagc tctgaaagag aggcactcat gtcagaactc aagatgatga 120
 cccagctggg aagccacgag aatattgtga acctgctggg ggcgtgcaca ctgtcaggac 180
 caatttactt gatttttgaa tactgttgct atgggtgatct tctcaactat ctaagaagta 240
 aaagagaaaa atttcacagg acttggacag agattttcaa ggaacacaat ttcagttttt 300
 accccacttt ccaatcacat ccaaattcca gcatgcctgg ttcaagagaa gttcagatac 360
 acccggactc ggatcaaatc tcagggtctt atgggaattc atttcactct gaagatgaaa 420

ttgaatatga aaaccaaaaa aggctggaag aagaggagga cttgaatgtg c 471

<210> 29
 <211> 517
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide: ATP-binding domain

<400> 29
 gagtttggga aggtactagg atcaggtgct tttggaaaag tgatgaacgc aacagcttat 60
 ggaattagca aaacaggagt ctcaatccag gttgccgtca aaatgctgaa agaaaaagca 120
 gacagctctg aaagagagggc actcatgtca gaactcaaga tgatgaccca gctgggaagc 180
 cacgagaata ttgtgaacct gctgggggcg tgcacactgt caggaccaat ttacttgatt 240
 tttgaatact gttgctatgg tgatcttctc aactatctaa gaagtaaaag agaaaaattt 300
 cacaggactt ggacagagat tttcaaggaa cacaatttca gtttttacct cactttccaa 360
 tcacatccaa attccagcat gcctggttca agagaagttc agatacacc ggactcggat 420
 caaatctcag ggcttcatgg gaattcattt cactctgaag atgaaattga atatgaaaac 480
 caaaaaaggc tggaagaaga ggaggacttg aatgtgc 517

<210> 30
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(19)
 <223> ribonucleotides

<220>
 <221> misc_feature
 <222> (20)..(21)
 <223> deoxyribonucleotides

<400> 30
 gguuauquac aggaacgcat t 21

<210> 31
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(19)
 <223> ribonucleotides

 <220>
 <221> misc_feature
 <222> (20)..(21)
 <223> deoxyribonucleotides

 <400> 31
 ugcguuccug uacauaacct t 21

 <210> 32
 <211> 19
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: A partial cDNA sequence of ATP-binding domain

 <400> 32
 ggtactagga tcaggtgct 19

 <210> 33
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: siRNA

 <400> 33
 gguacuagga ucaggugcu 19

 <210> 34
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: siRNA

 <400> 34
 agcaccugau ccuaguacc 19

 <210> 35
 <211> 19
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: A partial cDNA sequence of TK domain

 <400> 35
 caggagtctc aatccaggt 19

<210> 36
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: siRNA

 <400> 36
 caggagucuc aauccaggu 19

<210> 37
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: siRNA

 <400> 37
 accuggauug agacuccug 19

<210> 38
 <211> 19
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: A partial cDNA sequence of FLT3/ITD domain

 <400> 38
 tatgaatatg atctcaaat 19

<210> 39
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: siRNA

 <400> 39
 uaugaaauug aucucaaau 19

<210> 40
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic oligonucleotide: siRNA

 <400> 40
 auuugagauc auauucaua 19



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

COPY

U.S. APPLICATION NUMBER NO. 10/574,904	FIRST NAMED APPLICANT Masazumi Yasumoto	ATTY. DOCKET NO. 14220714PUS1
INTERNATIONAL APPLICATION NO. PCT/JP04/14851		
LA. FILING DATE 10/07/2004		PRIORITY DATE 10/09/2003

2292
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH, VA 22040-0747

CONFIRMATION NO. 7136
371 FORMALITIES LETTER



Date Mailed: 10/20/2008

SM KH
Sequence Listing
11/20/08

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to comply with the sequence rules, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.

<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

LAMONT M HUNTER

Telephone: (703) 308-9140 EXT 201